ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
+$0.18 today
- Market cap
- $7.13B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
Volume 15.77M
Average 16.40M
IBRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ImmunityBio, Inc.NASDAQ: IBRX
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $68.96M rose 35.9% year over year, ahead of the +33.2% change in trailing-twelve-month research & development. Sequentially, it rose 19.5% from the prior quarter. Over 3 fiscal years it compounded at -5.7% a year.
Context
- Research & development amounted to 183.5% of revenue in FY2025, down 1106.1 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +35.9% holds above the trailing-twelve-month pace of +33.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 207.88M USD
- Year-over-year change
- +9.3%
- 4-year CAGR
- +1.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 207.88M | +9.3% |
| FY2024 | 2024-12-31 | 190.14M | -18.2% |
| FY2023 | 2023-12-31 | 232.37M | -6.4% |
| FY2022 | 2022-12-31 | 248.15M | +26.6% |
| FY2021 | 2021-12-31 | 195.96M | — |
Research & Development vs competitors
How IBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +33.2% is the highest of 11, against a peer median of -12.2%.
- Research & development amounts to 138.2% of revenue for IBRX, versus a peer median of 74.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.66B USD | -23.6% | -1.7% | 105.3% | |
| LTM Jun 2026 | €2.18B EUR | -0.6% | +9.6% | 82.6% | |
| LTM Mar 2026 | $446.24M USD | -15.0% | -3.0% | 681.3% | |
| LTM Sep 2026 | $378.58M USD | -9.4% | +7.3% | 27.9% | |
| LTM Mar 2026 | $259.11M USD | +17.2% | +34.4% | 67.2% | |
| LTM Sep 2026 | $252.23M USD | +33.2% | -5.7% | 138.2% | |
| LTM Sep 2026 | $241.88M USD | -19.7% | +0.6% | 63.8% | |
| LTM Mar 2026 | €201.11M EUR | +27.4% | +19.9% | 539.2% | |
| LTM Mar 2026 | $129.09M USD | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $88.91M USD | -7.1% | -0.2% | — | |
| LTM Mar 2026 | $10.18M USD | -92.4% | -48.4% | 44.0% | |
| Peer median (excluding IBRX) | — | -12.2% | +0.2% | 74.9% | |
Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 934K | 240K | 622K | 14.75M | 113.29M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 753K |
| Gross Profit | 934K | 240K | 622K | 14.75M | 112.54M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 99.3% |
| Research & Development | 195.96M | 248.15M | 232.37M | 190.14M | 207.88M |
| Selling, General & Admin | 135.26M | 102.71M | 129.62M | 168.78M | 147.18M |
| Operating Expenses | 331.21M | 351.54M | 362.87M | 358.93M | 368.56M |
| Depreciation & Amortization | 14.24M | 18.26M | 18.51M | 17.55M | 15.53M |
| EBITDA | (320.75M) | (351.88M) | (478.66M) | (264.43M) | (223.56M) |
| EBITDA Margin | -34341.8% | -146617.1% | -76955.5% | -1793.4% | -197.3% |
| Operating Income | (330.28M) | (351.3M) | (362.25M) | (344.18M) | (256.03M) |
| Operating Margin | -35361.9% | -146374.2% | -58239.5% | -2334.2% | -226.0% |
| Interest Income | 836K | 2.71M | 863K | 2.4M | 6.7M |
| Interest Expense | 14.85M | 47.15M | 86.72M | 131.66M | 112.53M |
| Other Income / Expenses | (19.56M) | (65.99M) | (221.64M) | (69.46M) | (95.58M) |
| Income Before Tax | (349.84M) | (417.29M) | (583.89M) | (413.65M) | (351.61M) |
| Pre-Tax Margin | -37456.0% | -173869.2% | -93873.3% | -2805.3% | -310.4% |
| Income Tax Expense | 9K | 34K | (40K) | 0 | (135K) |
| Net Income | (346.79M) | (416.57M) | (583.2M) | (413.56M) | (351.4M) |
| Net Margin | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% |
| EPS (Basic) | (0.89) | (1.04) | (1.15) | (0.59) | (0.38) |
| EPS (Diluted) | (0.89) | (1.04) | (1.15) | (0.62) | (0.38) |
| Weighted Avg Shares | 389.23M | 399.9M | 508.64M | 697.31M | 919.86M |
| Weighted Avg Shares (Diluted) | 389.23M | 399.9M | 508.64M | 700.44M | 919.86M |
ImmunityBio, Inc.
NASDAQ:IBRX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.